Hims' expansion into selling non-FDA-approved multi-cancer early detection tests raises concerns among researchers. Offering these to its relatively young, low-risk user base could lead to false positives, triggering unnecessary and costly 'diagnostic odysseys' for patients who are merely worried.
Related Insights
Contrary to trends in wellness, a full-body MRI doesn't catch cancer early. A mass visible on an MRI already contains billions of cells and may have spread. Furthermore, it often leads to a rabbit hole of invasive tests for benign abnormalities, causing unnecessary harm.
Current FDA rules force a binary choice: a wellness product with no medical claims or a highly regulated medical device. A third category for 'screeners' could unlock innovation, allowing devices to flag risks (e.g., hypertension indicators) without making a formal diagnosis.
Recent FDA guidance distinguishes general wellness wearables from high-risk medical devices like pacemakers, giving companies like Oura more leeway for innovation. This aims to transform wearables into 'digital health screeners' that provide early disease warnings, encouraging earlier intervention and potentially lowering healthcare costs by changing behavior before chronic conditions escalate.
Dr. Deb Schrag suggests the main challenge for new molecular cancer screening technologies is not invention, but implementation. The critical task will be deploying these tools at a population scale and effectively managing the logistical challenge of distinguishing true positives from false alarms.
Bypassing complex gene sequencing, a new diagnostic from Asama Health leverages basic physics. It identifies cancerous DNA by measuring changes in electrical resistance caused by altered methylation patterns. This simple, disruptive approach promises a faster, more accessible method for early cancer detection.
While wearables generate vast amounts of health data, the medical system lacks the evidence to interpret these signals accurately for healthy individuals. This creates a risk of false positives ('incidentalomas'), causing unnecessary anxiety and hindering adoption of proactive health tech.
With over 5,000 oncology drugs in development and a 9-out-of-10 failure rate, the current model of running large, sequential clinical trials is not viable. New diagnostic platforms are essential to select drugs and patient populations more intelligently and much earlier in the process.
Applying traditional, broad primary care launch strategies to highly targeted specialty therapies is a major risk. The complexity of stakeholders and decision-making in areas like oncology means old playbooks can make a company's efforts completely irrelevant.
The current healthcare model is backwards. It's more cost-effective to proactively get comprehensive diagnostics like blood work done twice a year than to rely on multiple, expensive doctor visits after symptoms appear. This preventative approach catches diseases earlier and reduces overall system costs.
The popularity of at-home diagnostics and health protocols isn't just about clinical outcomes. It fulfills a deep-seated human need for control over one's health, a feeling the traditional 'wait and see' medical system often denies patients.